In this episode,, of Virginia Commonweath University joins guest host , of the Cleveland Clinic to discuss the and its impact on the treatment of HER2-positive breast cancer.
And, talks about whether it’s better for physicians to be vague about prognosis. Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford (Calif.) University and is also a columnist for Hematology News. More from Dr. Yurkiewicz .
Subscribe to Blood & Cancer here: